RxDoctor Payments Data

Ahmad Shah Mohammad, MD

Neurology · la Mesa, CANPI 1902973472

Payments from drug & device makers

$76,386in general payments, 2019–2025

Across 652 payments — averaging $117.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$61K
  • Boston Scientific$2K
  • SK Life Science, Inc.$1K
  • Lundbeck LLC$1K
  • Biogen$1K
  • UCB, Inc.$1K
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$2,46015%
  • Speaking & faculty fees$600%
  • Travel & lodging$1,0186%
  • Food & beverage$12,67177%
  • Education$1591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)105$61,277
Boston Scientific15$1,635
SK Life Science, Inc.12$1,480
Lundbeck LLC9$1,378
Biogen60$1,173
UCB, Inc.44$1,123
Teva Pharmaceuticals USA, Inc.51$852
Eisai Inc.33$703
Neurelis, Inc.30$570
Lilly USA, LLC23$483
Neurocrine Biosciences, Inc.21$452
Novartis20$412
Amgen(2 entities)20$403
Genentech USA, Inc.17$367
Amneal Pharmaceuticals LLC14$300
Sunovion Pharmaceuticals Inc.21$287
Acadia Pharmaceuticals Inc13$283
Sanofi12$231
Otsuka America Pharmaceutical, Inc.9$204
Livanova USA, Inc.8$191
MDD US Operations, LLC8$166
Imperative Care, Inc1$154
TG Therapeutics, Inc.5$139
Bausch Health US, LLC9$139
Kyowa Kirin, Inc.7$126
Johnson & Johnson1$125
Banner Life Sciences, LLC5$103
Biohaven Pharmaceutical Holding Company Ltd.5$103
Avanir Pharmaceuticals, Inc.5$99
Sumitomo Pharma America, Inc.6$99
Genentech, Inc.4$94
AstraZeneca(2 entities)4$92
Axsome Therapeutics, Inc.4$91
Pfizer4$81
Biohaven Pharmaceuticals, Inc.4$78
Aucta Pharmaceuticals, Inc.4$75
Akcea Therapeutics, Inc.2$69
Acorda Therapeutics, Inc3$60
Scilex Pharmaceuticals Inc.2$58
Bristol Myers Squibb3$56
Vertical Pharmaceuticals, LLC3$52
GE HealthCare1$46
Vanda Pharmaceuticals Inc.2$44
Octapharma USA, Inc.2$43
Supernus Pharmaceuticals, Inc.2$36
Chiesi USA, Inc.1$26
Merz Pharmaceuticals, LLC1$25
Novo Nordisk1$25
Abbott1$25
Impel Pharmaceuticals Inc.1$24
Promius Pharma LLC2$24
Alnylam Pharmaceuticals Inc.1$24
Corium, LLC1$24
Upsher-smith Laboratories LLC2$24
Adamas Pharmaceuticals, Inc.1$22
Avion Pharmaceuticals1$19
Takeda Pharmaceuticals U.S.A., Inc.1$18
Insightec,inc1$17
Arbor Pharmaceuticals, Inc.1$17
Tanabe Pharma America, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,386 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$57,874
Medicare patients
144
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate13$61,830
Nurtec OdtRimegepant Sulfate55$61,002
NamzaricMemantine Hcl/Donepezil Hcl39$21,915
Aimovig AutoinjectorErenumab-Aooe29$20,285
NuedextaDextromethorphan Hbr/Quinidine25$15,177
Levetiracetam147$8,265
Memantine Hcl289$6,277
Rasagiline Mesylate23$6,147
Memantine Hcl ErMemantine Hcl61$5,347
Carbidopa-LevodopaCarbidopa/Levodopa121$3,978
Selegiline Hcl28$3,683
Lacosamide28$3,376
Donepezil Hcl412$3,260
Gabapentin315$2,906
Carbamazepine26$2,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$283$61,83013 claims
PfizerNurtec Odt$81$61,00255 claims
AbbVieNamzaric$61,277$21,91539 claims
Avanir Pharmaceuticals, Inc.Nuedexta$99$15,17725 claims
Upsher-smith Laboratories LLCTopiramate$24$1,26247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →